News > ProtAffin

News > Overview

We invite you to look through our recent company press releases, and read articles about us that have been in the press and other media outlets. For any specific enquiries, please email us at .(JavaScript must be enabled to view this email address)

Latest Press Releases

Date	Title	Download
14 Dec 2011	ProtAffin AG receives key grant for preclinical and clinical development
20 Oct 2011	ProtAffin AG announces preclinical data in Multiple Sclerosis for MCP-1 decoy program

ProtAffin in the News

Date	Title
16 Feb 2012	CEO Jason Slingsby speaks at a recent SCRIP Round Table.	Website

All Press Releases

Date	Title	Download
14 Dec 2011	ProtAffin AG receives key grant for preclinical and clinical development
20 Oct 2011	ProtAffin AG announces preclinical data in Multiple Sclerosis for MCP-1 decoy program
26 Sep 2011	ProtAffin AG appoints Dr Mike Bartley as Chief Development Officer
25 Jul 2011	ProtAffin AG strengthens Supervisory Board
14 Mar 2011	ProtAffin AG granted patent in EU for CellJammer® discovery technology
15 Nov 2010	ProtAffin AG receives grant from FFG for preclinical development of PA401in COPD
21 Sep 2010	ProtAffin AG announces preclinical data in COPD for lead product PA401
27 Jul 2010	ProtAffin AG signs manufacturing contract for PA401 with CMC Biologics A/S
11 Sep 2009	ProtAffin AG granted patent in USA for lead anti-inflammatory product PA401
27 Apr 2009	ProtAffin AG completes €14 million Series B financing
23 Jan 2009	ProtAffin AG granted patent in EU for lead anti-inflammatory product PA401
05 Sep 2008	ProtAffin AG granted Orphan Drug Designation in the US for lead anti-inflammatory product
18 Jul 2008	ProtAffin AG granted Orphan Medicinal Product Designation by EMEA for lead anti-inflammatory product
02 Apr 2008	ProtAffin AG receives research grant
14 Jan 2008	ProtAffin AG completes second closing of Series A financing
04 May 2007	ProtAffin AG secures Series A financing